1. Home
  2. GBR vs GNPX Comparison

GBR vs GNPX Comparison

Compare GBR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Concept Energy Inc

GBR

New Concept Energy Inc

HOLD

Current Price

$0.74

Market Cap

3.2M

Sector

Energy

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$3.34

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GBR
GNPX
Founded
1978
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
2.9M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
GBR
GNPX
Price
$0.74
$3.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.8K
95.3K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$155,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.16
N/A
52 Week Low
$0.62
$0.16
52 Week High
$1.31
$12.97

Technical Indicators

Market Signals
Indicator
GBR
GNPX
Relative Strength Index (RSI) N/A 40.54
Support Level N/A $1.88
Resistance Level N/A $3.62
Average True Range (ATR) 0.00 0.19
MACD 0.00 -0.02
Stochastic Oscillator 0.00 14.47

Price Performance

Historical Comparison
GBR
GNPX

About GBR New Concept Energy Inc

New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: